ArticleCurrent oncology (Toronto, Ont.)2026

Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.

Angel Kwan Qi Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.